Rovi stock trades 32.24 percent below its 52-week high

Published on 10/07/2026 at 14:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi stock costs EUR 58.75 on October 7, 2026 after EUR 57.56, plus 2.07 percent. First-half revenue rose 13.00 percent to EUR 357.00 million.

Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi stock (ISIN ES0157261019) was trading at EUR 58.75 at Lang & Schwarz on October 7, 2026 at 2:41 p.m. CEST, plus 2.07 percent versus the prior close of EUR 57.56. The price stood 32.24 percent below its EUR 86.70 52-week high, putting the current market picture below the year's upper boundary.

First-half revenue sets the baseline

According to Yahoo Finance on July 23, 2026, total revenue increased 13.00 percent to EUR 357.00 million in the first half of 2026. Operating revenue rose 9.00 percent to EUR 344.20 million, while contract manufacturing revenue increased 38.00 percent to EUR 106.30 million.

The mix matters for the stock. Contract manufacturing supplied the clearest growth contribution, while the specialty pharmaceutical division generated EUR 237.80 million in first-half sales, up 0.20 percent from the same period of 2025.

Cash flow and heparin remain key

Rovi reported EUR 84.40 million in net profit for the first half of 2026, an increase of 113.00 percent from the first half of 2025, according to Yahoo Finance. Operating cash flow reached EUR 94.30 million, compared with EUR 28.00 million in the first half of 2025.

The report also showed a counterweight to the growth narrative. Heparin sales declined 4.00 percent to EUR 130.10 million in the first half of 2026, while Okedi sales rose 27.00 percent to EUR 34.00 million.

Results date gives the next reference point

Rovi lists November 5, 2026, for its first nine months 2026 financial results. That release will provide the next direct test of whether contract manufacturing growth continues to offset pressure in heparin sales.

At a market capitalization of EUR 3.0 billion on October 7, 2026, Rovi was valued between its EUR 53.10 52-week low and EUR 86.70 high. The share's 2.07 percent daily gain was positive, but the 32.24 percent gap to the high keeps the broader price picture measured. Price source: Lang & Schwarz, October 7, 2026 at 2:41 p.m. CEST, with a prior close of EUR 57.56. The further course of trading is shown by the continuously updated real-time quote of Rovi stock.